Stock Selection: DeepSeek's picks for 2026-09-29
DeepSeek picked SMMT, FCEL, IOVA, NVTS, CCL for a 1-day horizon. Portfolio return vs SPY: +1.32%. Picks that beat SPY: 80%.
| Experiment | Stock Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-29 |
| Measured to | 2026-09-30 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +1.32% |
| Picks that beat SPY | 80% |
| Benchmark return | +0.46% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | SMMT | +3.88% | 80% | +3.42% | Yes |
| 2 | FCEL | -1.92% | 75% | -2.38% | No |
| 3 | IOVA | +3.41% | 70% | +2.94% | Yes |
| 4 | NVTS | +1.77% | 65% | +1.31% | Yes |
| 5 | CCL | +1.76% | 60% | +1.30% | Yes |
The model's market view
US equity futures point to a modestly higher open as technology stocks stabilize and oil prices retreat, though ongoing Middle East tensions and elevated Treasury yields temper risk appetite. Small-cap and catalyst-driven names are likely to see outsized moves.
Why each pick
SMMT
AstraZeneca's $2 billion strategic equity investment at $18.36 per share, a 10% premium to the five-day VWAP, provides strong validation of Summit's ivonescimab program and removes near-term financing overhang. The stock is up ~22% premarket with analyst price targets moving higher (Citi to $43). Risks: The deal is not yet closed; ivonescimab FDA decision due Nov. 14 remains a binary event; premarket gains may fade if broader biotech sentiment weakens. Reference price is a premarket quote.
FCEL
Oppenheimer initiated coverage with an Outperform rating and a $24 price target, citing FuelCell as a differentiated provider of on-site power for the AI data center build-out. The company's $3.3B backlog and planned capacity expansion to 500 MW by FY2029 support a multi-year growth narrative. Risks: FuelCell remains unprofitable with a history of cash burn; the rally is driven by a single analyst note and may not sustain if broader market risk appetite fades. Reference price is a premarket quote.
IOVA
Iovance raised its FY2026 revenue guidance to $410–$420 million, well above the $402.8 million consensus, reflecting strong adoption of Amtagvi and Proleukin. The guidance hike clears a key overhang and signals accelerating commercial momentum. Risks: The company is still unprofitable and cash-burn dependent; competition in the TIL therapy space is intensifying; premarket gains of ~14% may attract profit-taking. Reference price is a premarket quote.
NVTS
Navitas was selected by the U.S. Army for the ALATTIS program to develop next-generation 10 kV silicon carbide power semiconductors, a significant validation of its technology. The stock is up ~10% premarket on elevated volume. Risks: The contract value is not disclosed; Navitas is a small-cap with high volatility and negative earnings; the rally may be short-lived if the broader semiconductor sector remains under pressure. Reference price is a premarket quote.
CCL
Carnival reported Q3 EPS of $1.43 on revenue of $8.44B, beating estimates, and the stock is up ~6.5% premarket. Strong booking trends and cost controls are offsetting higher fuel costs. Risks: The cruise operator faces geopolitical headwinds in Europe and elevated oil prices; the stock has fallen 27% YTD and any disappointment in forward guidance could reverse gains. Reference price is a premarket quote.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| ChatGPT | NVDA, KMX, AVGO, MU, NFLX | -2.53% | 0% |
| Muse Spark 1.1 | NVDA, XOM, AAPL, MSFT, AMZN | +1.11% | 80% |
| Perplexity | KOD, BKYI, SMMT, SOXL, ARM | -5.70% | 40% |
| Claude Sonnet 5.5 | XLV, XLE, NVDA, XLI, XLP | -0.61% | 0% |
| Gemini 3 Pro | META, NVDA, AMZN, GOOGL, MSFT | +1.54% | 80% |
| Grok 4.5 | NVDA, IOVA, SMMT, CCL, XOM | +1.56% | 80% |
Written up on ForecastNest Insights: Stock Selection: DeepSeek's picks for 2026-09-29.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.